Skip to main content
Premium Trial:

Request an Annual Quote

Roche Official: Leukemia, p53 Microarrays Next on the Agenda

SAN DIEGO, Feb. 22 (GenomeWeb News) - Following a talk at the Clinical Genomics conference here last week, Walter Koch, senior director of Roche's pharmacogenomics department, provided a few details concerning the company's upcoming leukemia microarray and p53 AmpliChip products, which are being produced using technology the company licensed from Affymetrix.

"We will need a diagnostic for resequencing p53 if [Roche's] MDM2-inhibitors make it through trials," Koch said of the company's AmpliChip p53 mutational analysis test. The cancer drugs are currently "close to Phase I," he said.

Koch also clarified the capabilities of an upcoming leukemia microarray, which will classify tumor cells into one of 20 subtypes, he said.

The leukemia classification microarray is slated for rollout during 2005 and into 2006, while the AmpliChip p53 test has been targeted for research use in 2006.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.